James C Yang

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. doi request reprint The adoptive transfer of cultured T cells for patients with metastatic melanoma
    James C Yang
    Surgery Branch, Center for Clinical Research, National Cancer Institute, Building 10A, Rm 3 5952, Bethesda, MD 20892, USA
    Clin Dermatol 31:209-19. 2013
  2. ncbi request reprint Bevacizumab for patients with metastatic renal cancer: an update
    James C Yang
    Surgery Branch, National Cancer Institute, Bethesda, Maryland 20892, USA
    Clin Cancer Res 10:6367S-70S. 2004
  3. pmc A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer
    James C Yang
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    N Engl J Med 349:427-34. 2003
  4. pmc Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer
    James C Yang
    Surgery Branch, Biostatistics and Data Management Section, Department of Pathology, National Cancer Institute NIH, Room 2B 37, Building 10, 9000 Rockville Pike, Bethesda, MD 20892, USA
    J Clin Oncol 21:3127-32. 2003
  5. pmc Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4
    Kimberly E Beck
    Surgery Branch and Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1201, USA
    J Clin Oncol 24:2283-9. 2006
  6. pmc Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma
    Steven A Rosenberg
    Center for Cancer Research, Surgery Branch, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 9:2973-80. 2003
  7. pmc Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines
    Franz O Smith
    Surgery Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892 1201, USA
    Clin Cancer Res 14:5610-8. 2008
  8. pmc Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen
    Laura A Johnson
    Surgery Branch, Hatfield Clinical Research Center, National Cancer Institute NIH, Bethesda, MD 20892, USA
    Blood 114:535-46. 2009
  9. pmc Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens
    Mark E Dudley
    Surgery Branch, National Cancer Institute, NIH, Bethesda, MD 20892 1201, USA
    J Clin Oncol 26:5233-9. 2008
  10. pmc Cell transfer therapy for cancer: lessons from sequential treatments of a patient with metastatic melanoma
    Steven A Rosenberg
    Center for Cancer Research, Surgery Branch, National Cancer Institute, National Institute of Health, Building 10, Room 2B42, 10 Center Drive, Bethesda, Maryland 20892, USA
    J Immunother 26:385-93. 2003

Detail Information

Publications72

  1. doi request reprint The adoptive transfer of cultured T cells for patients with metastatic melanoma
    James C Yang
    Surgery Branch, Center for Clinical Research, National Cancer Institute, Building 10A, Rm 3 5952, Bethesda, MD 20892, USA
    Clin Dermatol 31:209-19. 2013
    ..The antigens recognized by T cells, the techniques to procure and grow tumor reactive T cells, the conditioning of the recipient to optimize efficacy, and the results of clinical protocols are reviewed herein...
  2. ncbi request reprint Bevacizumab for patients with metastatic renal cancer: an update
    James C Yang
    Surgery Branch, National Cancer Institute, Bethesda, Maryland 20892, USA
    Clin Cancer Res 10:6367S-70S. 2004
    ..Future trials should consider combination therapies and strategies in which patients are treated through initial disease progression with antiangiogenic agents such as bevacizumab...
  3. pmc A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer
    James C Yang
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    N Engl J Med 349:427-34. 2003
    ..We conducted a clinical trial to evaluate bevacizumab, a neutralizing antibody against vascular endothelial growth factor, in patients with metastatic renal-cell carcinoma...
  4. pmc Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer
    James C Yang
    Surgery Branch, Biostatistics and Data Management Section, Department of Pathology, National Cancer Institute NIH, Room 2B 37, Building 10, 9000 Rockville Pike, Bethesda, MD 20892, USA
    J Clin Oncol 21:3127-32. 2003
    ..This three-arm randomized study compares response rates and overall survival of patients with metastatic renal cell cancer (RCC) receiving high-dose or one of two low-dose interleukin-2 (IL-2) regimens...
  5. pmc Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4
    Kimberly E Beck
    Surgery Branch and Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1201, USA
    J Clin Oncol 24:2283-9. 2006
    ..A report on the diagnosis, pathology, treatment, clinical outcome, and significance of the immune-mediated enterocolitis seen with ipilimumab is presented...
  6. pmc Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma
    Steven A Rosenberg
    Center for Cancer Research, Surgery Branch, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 9:2973-80. 2003
    ..The immunogenicity of these constructs was studied using peripheral blood mononuclear cells to measure epitope-specific release of IFN-gamma...
  7. pmc Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines
    Franz O Smith
    Surgery Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892 1201, USA
    Clin Cancer Res 14:5610-8. 2008
    ..v. interleukin-2 (IL-2) given either alone or in combination with a variety of melanoma vaccines...
  8. pmc Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen
    Laura A Johnson
    Surgery Branch, Hatfield Clinical Research Center, National Cancer Institute NIH, Bethesda, MD 20892, USA
    Blood 114:535-46. 2009
    ..This trial was registered at www.ClinicalTrials.gov as NCI-07-C-0174 and NCI-07-C-0175...
  9. pmc Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens
    Mark E Dudley
    Surgery Branch, National Cancer Institute, NIH, Bethesda, MD 20892 1201, USA
    J Clin Oncol 26:5233-9. 2008
    ..Here, we update that study and evaluate the safety and efficacy of two increased-intensity myeloablative lymphodepleting regimens...
  10. pmc Cell transfer therapy for cancer: lessons from sequential treatments of a patient with metastatic melanoma
    Steven A Rosenberg
    Center for Cancer Research, Surgery Branch, National Cancer Institute, National Institute of Health, Building 10, Room 2B42, 10 Center Drive, Bethesda, Maryland 20892, USA
    J Immunother 26:385-93. 2003
    ....
  11. pmc Immunization of patients with metastatic melanoma using both class I- and class II-restricted peptides from melanoma-associated antigens
    Giao Q Phan
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institute of Health, Bethesda, MD 20892 1502, USA
    J Immunother 26:349-56. 2003
    ..Moreover, the sequential, nonrandomized nature of patient enrollment for the two trials may account for the differences in immunologic response...
  12. pmc Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
    Giao Q Phan
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 100:8372-7. 2003
    ..This study establishes CTLA-4 as an important molecule regulating tolerance to "self" antigens in humans and suggests a role for CTLA-4 blockade in breaking tolerance to human cancer antigens for cancer immunotherapy...
  13. pmc CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma
    Peter A Prieto
    Surgery Branch, National Cancer Institute, NIH, Bldg 10 CRC, Room 3 5760, 10 Center Drive, Bethesda, MD 20892, USA
    Clin Cancer Res 18:2039-47. 2012
    ..Treatment with ipilimumab can cause objective tumor responses in patients with metastatic melanoma. We have treated 177 evaluable patients in three clinical trials and have long-term follow-up to evaluate the durability of responses...
  14. pmc Cancer regression in patients after transfer of genetically engineered lymphocytes
    Richard A Morgan
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, USA
    Science 314:126-9. 2006
    ..This study suggests the therapeutic potential of genetically engineered cells for the biologic therapy of cancer...
  15. pmc Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma
    Ajay V Maker
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20814, USA
    J Immunother 29:455-63. 2006
    ....
  16. pmc Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study
    Ajay V Maker
    Surgery Branch, National Cancer Institute, National Institutes of Health, CRC Room 3 3940, 10 Center Drive, MSC 1201, Bethesda, MD 20814, USA
    Ann Surg Oncol 12:1005-16. 2005
    ..In this study, we assessed the antitumor activity and autoimmune toxicity of CTLA-4 blockade in combination with an immune-activating stimulus, interleukin (IL)-2, in patients with metastatic melanoma...
  17. pmc Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4
    Peter Attia
    Surgery Branch, National Cancer Institute, National Institutes of Health, CRC, Room 3W 3940, 10 Center Dr, Bethesda, MD 20892 1201, USA
    J Clin Oncol 23:6043-53. 2005
    ..We have now treated 56 patients to evaluate two different dose schedules of anti-CTLA-4 and to explore the relationship between autoimmunity and tumor regression...
  18. pmc Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma
    Steven A Rosenberg
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 175:6169-76. 2005
    ..Further, the induction of even high levels of antitumor T cells may be insufficient to alter tumor progression...
  19. pmc Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma
    Mark E Dudley
    Surgery Branch, National Cancer Institute, NIH, CRC 3 3940, 10 Center Dr MSC 1201, Bethesda MD 20892 1202, USA
    J Clin Oncol 23:2346-57. 2005
    ..We investigated the combination of lymphodepleting chemotherapy followed by the adoptive transfer of autologous tumor reactive lymphocytes for the treatment of patients with refractory metastatic melanoma...
  20. pmc Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer
    Joseph A Blansfield
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 1201, USA
    J Immunother 28:593-8. 2005
    ..The characteristics, clinical course, laboratory values, radiographic findings, and treatment of these 8 patients are the focus of this report...
  21. pmc Different adjuvanticity of incomplete freund's adjuvant derived from beef or vegetable components in melanoma patients immunized with a peptide vaccine
    Steven A Rosenberg
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1201, USA
    J Immunother 33:626-9. 2010
    ..A survey of ongoing clinical trials listed in ClinicalTrials.gov revealed 36 trials currently accruing patients that are using the olive-derived Montanide ISA 51 IFA...
  22. pmc Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1
    Paul F Robbins
    National Institutes of Health, National Cancer Institute, Surgery Branch, Bethesda, MD 20892 1201, USA
    J Clin Oncol 29:917-24. 2011
    ....
  23. pmc Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy
    Steven A Rosenberg
    Surgery Branch, National Cancer Institute, NIH, Bethesda, Maryland, USA
    Clin Cancer Res 17:4550-7. 2011
    ..We investigated the ability of adoptive cell transfer utilizing autologous tumor-infiltrating lymphocytes (TIL) to mediate durable complete regressions in heavily pretreated patients with metastatic melanoma...
  24. pmc Ocular and systemic autoimmunity after successful tumor-infiltrating lymphocyte immunotherapy for recurrent, metastatic melanoma
    Steven Yeh
    National Eye Institute, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20814, USA
    Ophthalmology 116:981-989.e1. 2009
    ..To describe the ophthalmic and systemic autoimmune findings after successful adoptive cell transfer of ex vivo expanded, autologous tumor-reactive tumor-infiltrating lymphocytes (TIL) for metastatic melanoma...
  25. pmc Characterization of a novel nonclassical T cell clone with broad reactivity against human renal cell carcinomas
    Qiong J Wang
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 181:3769-76. 2008
    ..Our findings suggest that clone HC/2G-1 represents a novel type of CD4(+) cell that has broad TCR-mediated recognition of a determinant widely expressed by RCC...
  26. doi request reprint Liver resection for metastatic melanoma with postoperative tumor-infiltrating lymphocyte therapy
    R Taylor Ripley
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Ann Surg Oncol 17:163-70. 2010
    ..Patients with metastatic melanoma to the liver (MML) have a median survival of 4 to 6 months. This study evaluated patients who underwent liver resection with intent to receive postoperative tumor-infiltrating lymphocyte (TIL) therapy...
  27. pmc Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2
    Richard A Morgan
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Mol Ther 18:843-51. 2010
    ..We speculate that the large number of administered cells localized to the lung immediately following infusion and were triggered to release cytokine by the recognition of low levels of ERBB2 on lung epithelial cells...
  28. doi request reprint Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma
    Richard E Royal
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    J Immunother 33:828-33. 2010
    ..0 mg/kg/dose is ineffective for the treatment of advanced pancreas cancer. However, a significant delayed response in one subject of this trial suggests that immunotherapeutic approaches to pancreas cancer deserve further exploration...
  29. pmc Altered CD8(+) T-cell responses when immunizing with multiepitope peptide vaccines
    Steven A Rosenberg
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Immunother 29:224-31. 2006
    ....
  30. doi request reprint Tumor-specific CD4+ melanoma tumor-infiltrating lymphocytes
    Kevin M Friedman
    Surgery Branch, National Cancer Institute, NIH, Bethesda, MD 20892 1201, USA
    J Immunother 35:400-8. 2012
    ..These results demonstrate that at least 20% of metastatic melanomas contain CD4+ lymphocytes with specific tumor recognition and suggest a possible role for CD4+ cells in the effectiveness of adoptive cell therapy...
  31. ncbi request reprint Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis
    Michael R Robinson
    National Eye Institute, National Institutes of Health, Bethesda, Maryland 20892 1863, USA
    J Immunother 27:478-9. 2004
    ..This suggests that CTLA-4 is an important regulatory molecule for maintenance of tolerance to melanosomal antigens and prevention of uveitis...
  32. pmc High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma : a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006
    Jacob A Klapper
    Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Cancer 113:293-301. 2008
    ..The current study presents the authors' 20-year experience administering this immunotherapeutic agent...
  33. pmc Immunization of HLA-A*0201 and/or HLA-DPbeta1*04 patients with metastatic melanoma using epitopes from the NY-ESO-1 antigen
    Hung T Khong
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 1502, USA
    J Immunother 27:472-7. 2004
    ..This result raises questions about the use of synthetic peptides derived from NY-ESO-1 as a sole form of immunization...
  34. pmc Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes
    Mark E Dudley
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20902, USA
    Science 298:850-4. 2002
    ..This approach presents new possibilities for the treatment of patients with cancer as well as patients with human immunodeficiency virus-related acquired immunodeficiency syndrome and other infectious diseases...
  35. pmc Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis
    James C Yang
    Surgery Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
    J Immunother 30:825-30. 2007
    ..These regressions are highly associated with other immune-mediated events of presumed autoimmune origin by mechanisms as yet undefined...
  36. pmc Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy
    Richard A Morgan
    Surgery Branch, National Cancer Institute, Bethesda, MD 20892, USA
    J Immunother 36:133-51. 2013
    ....
  37. doi request reprint Tumor infiltrating lymphocyte therapy for metastatic melanoma: analysis of tumors resected for TIL
    Stephanie L Goff
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1201, USA
    J Immunother 33:840-7. 2010
    ..As more centers begin exploring the use of adoptive transfer with TIL, this compendium may provide a framework for therapeutic decision making and future investigation...
  38. pmc CD8+ enriched "young" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma
    Mark E Dudley
    Surgery Branch and Radiation Oncology Branch, National Cancer Institute, Bethesda, Maryland 20892 1201, USA
    Clin Cancer Res 16:6122-31. 2010
    ..However, the generation of a unique tumor-reactive TIL culture for each patient may be prohibitively difficult. We therefore investigated the clinical and immunologic impact of unscreened, CD8+ enriched "young" TIL...
  39. ncbi request reprint Generating renal cancer-reactive T cells using dendritic cells (DCs) to present autologous tumor
    Qiong J Wang
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunother 28:551-9. 2005
    ..The technique of using DCs to present whole-tumor cells can consistently generate both CD4+ and CD8+ RCC-reactive T cells for use in both antigen identification and therapeutic protocols...
  40. pmc Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen
    Steven A Rosenberg
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1502, USA
    Hum Gene Ther 14:709-14. 2003
    ..We were thus unable to demonstrate significant clinical or immunologic responses to plasmid DNA encoding the "self" nonmutated gp100 tumor antigen...
  41. pmc B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells
    James N Kochenderfer
    Experimental Transplantation and Immunology Branch, National Cancer Institute NCI, Bethesda, MD 20892, USA
    Blood 119:2709-20. 2012
    ....
  42. pmc Vaccine-stimulated, adoptively transferred CD8+ T cells traffic indiscriminately and ubiquitously while mediating specific tumor destruction
    Douglas C Palmer
    National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 173:7209-16. 2004
    ..The ability to induce ubiquitous homing and specific tumor destruction may be important in the case of noninflammatory metastatic tumor foci...
  43. pmc A pilot study of antiangiogenic therapy with bevacizumab and thalidomide in patients with metastatic renal cell carcinoma
    Dina M Elaraj
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Immunother 27:259-64. 2004
    ....
  44. pmc Assessment of ovarian function after preparative chemotherapy and total body radiation for adoptive cell therapy
    Russell C Langan
    Surgery Branch, National Cancer Institute, Clinical Center, National Institutes of Health, Bethesda, MD 20892 120, USA
    J Immunother 34:397-402. 2011
    ..Younger age at treatment was associated with a higher frequency of normal ovarian function posttreatment, whereas adding total body radiation was associated with a high risk of ovarian failure...
  45. pmc Selection of CD8+PD-1+ lymphocytes in fresh human melanomas enriches for tumor-reactive T cells
    Takashi Inozume
    Surgery Branch, National Cancer Institute, National Institute of Health, Bethesda, MD 20892, USA
    J Immunother 33:956-64. 2010
    ..As a consequence, the PD-1 receptor can be a useful biomarker for enriching tumor-specific T cells from fresh melanomas...
  46. pmc Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade
    Stephanie G Downey
    Surgery Branch, Center for Cancer Research, National Cancer Institute National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, USA
    Clin Cancer Res 13:6681-8. 2007
    ..We have now treated 139 patients in two trials and have sufficient follow-up to examine factors associated with clinical response...
  47. pmc Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma
    John F Toso
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 10, Room 2B42, Bethesda, MD 20892, USA
    J Clin Oncol 20:142-52. 2002
    ..These findings led to the present phase I study of the intravenous infusion of VNP20009 to patients with metastatic cancer...
  48. pmc Safety and efficacy of high-dose interleukin-2 therapy in patients with brain metastases
    Lisa M Guirguis
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Immunother 25:82-7. 2002
    ..Carefully selected patients with brain metastases can safely receive high-dose interleukin-2, and some can experience a response to treatment at intracranial and extracranial disease sites...
  49. pmc A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma
    Mark E Dudley
    Surgery Branch, National Cancer Institute, Building 10, Room 2B08, 9000 Rockville Pike, Bethesda, MD 20892, USA
    J Immunother 25:243-51. 2002
    ..This study established a nonmyeloablative-conditioning regimen that could be safely administered in conjunction with adoptive T-cell transfer and IL-2 in patients with metastatic melanoma...
  50. doi request reprint IL-17 secreted by tumor reactive T cells induces IL-8 release by human renal cancer cells
    Takashi Inozume
    Surgery Branch, National Cancer Institute, National Institute of Health, Bethesda, MD 20892, USA
    J Immunother 32:109-17. 2009
    ..This report extends the known bidirectional interactions between immune cells and malignant cells in the tumor microenvironment that can shape and modulate the host immune response to cancer...
  51. ncbi request reprint Prospective analysis of circulating endostatin levels in patients with renal cell carcinoma
    Andrew L Feldman
    Surgery Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA
    Cancer 95:1637-43. 2002
    ....
  52. pmc A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer
    Michael H Kershaw
    Surgery Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA
    Clin Cancer Res 12:6106-15. 2006
    ..A phase I study was conducted to assess the safety of adoptive immunotherapy using gene-modified autologous T cells for the treatment of metastatic ovarian cancer...
  53. pmc T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis
    Maria R Parkhurst
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Mol Ther 19:620-6. 2011
    ..It also emphasizes the destructive power of small numbers of highly avid T cells and the limitations of using CEA as a target for cancer immunotherapy...
  54. pmc Mutated PPP1R3B is recognized by T cells used to treat a melanoma patient who experienced a durable complete tumor regression
    Yong Chen Lu
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 190:6034-42. 2013
    ..This study also provides an impetus to develop personalized immunotherapy targeting tumor-specific, mutated Ags...
  55. pmc Cancer immunotherapy: moving beyond current vaccines
    Steven A Rosenberg
    Surgery Branch of the Center for Cancer Research at the National Cancer Institute, Building 10, Room 2B42, 10 Center Drive, MSC 1502 Bethesda, Maryland 20892 1502, USA
    Nat Med 10:909-15. 2004
    ..6%), and comparable to the results obtained by others. We consider here results in cancer vaccine trials and highlight alternate strategies that mediate cancer regression in preclinical and clinical models...
  56. pmc Adoptive cell transfer: a clinical path to effective cancer immunotherapy
    Steven A Rosenberg
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, Maryland 20892, USA
    Nat Rev Cancer 8:299-308. 2008
    ....
  57. pmc Development of a genetically-modified novel T-cell receptor for adoptive cell transfer against renal cell carcinoma
    Qiong J Wang
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol Methods 366:43-51. 2011
    ..A phase I/II clinical trial, adoptively transferring autologous PBL transduced with this modified TCR has just begun in patients with metastatic RCC...
  58. ncbi request reprint Treatment of oligometastases after successful immunotherapy
    James C Yang
    Surgery Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA
    Semin Radiat Oncol 16:131-5. 2006
    ..These data indicate that a surprising percentage of such patients can enjoy durable disease-free survival after surgical removal of their oligometastases, and, for a significant minority, it appears to be curative...
  59. pmc Molecular identification of an MHC-independent ligand recognized by a human {alpha}/{beta} T-cell receptor
    Ken ichi Hanada
    National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Blood 117:4816-25. 2011
    ....
  60. pmc Distinctive features of the differentiated phenotype and infiltration of tumor-reactive lymphocytes in clear cell renal cell carcinoma
    Qiong J Wang
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    Cancer Res 72:6119-29. 2012
    ..Our results suggest that RCC-reactive TIL do exist in situ, but may be difficult to recover and study because of proliferative exhaustion, driven by tumor-expressed CD70...
  61. doi request reprint Successful treatment of melanoma brain metastases with adoptive cell therapy
    Jenny J Hong
    National Cancer Institute, Surgery Branch and The Clinical Center of the NIH, Radiology and Imaging Sciences, Bethesda, Maryland, USA
    Clin Cancer Res 16:4892-8. 2010
    ..The response rate and duration of melanoma brain metastases, as well as the overall response rate, response duration, and survival for these patients, are presented...
  62. ncbi request reprint Immunotherapy for renal cell cancer
    James C Yang
    Surgery Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    J Clin Oncol 24:5576-83. 2006
    ..As the array of biologic therapies for renal cancer expands with the approval of tyrosine kinase inhibitors, immunotherapy, the only modality that can cure widespread renal cancer, must not be overlooked...
  63. pmc Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma
    Mark E Dudley
    Surgery Branch, National Cancer Institute, National Institutes of Health, CRC 3W 5752, 10 Center Dr, Bethesda, MD 20892, USA
    J Clin Oncol 31:2152-9. 2013
    ..The optimal TIL product for ACT is unknown...
  64. ncbi request reprint Novel biochemistry: post-translational protein splicing and other lessons from the school of antigen processing
    Ken ichi Hanada
    Surgery Branch, National Cancer Institute, National Institutes of Health, Clinical Research Center, Bethesda, MD 20892 1201, USA
    J Mol Med (Berl) 83:420-8. 2005
    ....
  65. ncbi request reprint Linking laboratory and clinical research: the development of molecularly targeted therapeutics inside the national cancer institute center for cancer research
    J Carl Barrett
    National Cancer Institute Center for Cancer Research, National Institutes of Health, Bethesda, MD 20892, USA
    Clin Adv Hematol Oncol 1:302-6. 2003
    ..Its infrastructure supports the iterative flow of information from the bench to the bedside and from the bedside to the bench, expediting the delivery of molecularly based therapeutics to cancer patients...
  66. ncbi request reprint Immune recognition of a human renal cancer antigen through post-translational protein splicing
    Ken ichi Hanada
    Surgery Branch, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Building10, Room 2B42, Bethesda, Maryland 20892, USA
    Nature 427:252-6. 2004
    ..The occurrence of protein splicing in vertebrates has important implications for the complexity of the vertebrate proteome and for the immune recognition of self and foreign peptides...
  67. ncbi request reprint Vitespen: a vaccine for renal cancer?
    James C Yang
    Surgery Branch, National Cancer Institute, Bethesda, MD 20892, USA
    Lancet 372:92-3. 2008
  68. pmc Rapid production of clinical-grade gammaretroviral vectors in expanded surface roller bottles using a "modified" step-filtration process for clearance of packaging cells
    Steven A Feldman
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Hum Gene Ther 22:107-15. 2011
    ..To date, this platform has generated five clinical-grade gammaretroviral vector products, four of which are now being used in adoptive cell therapy clinical trials for the treatment of a variety of solid cancers...
  69. pmc αβ T cell receptors that do not undergo major histocompatibility complex-specific thymic selection possess antibody-like recognition specificities
    Anastasia N Tikhonova
    Experimental Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Immunity 36:79-91. 2012
    ..This study demonstrates that, without MHC-specific thymic selection, αβTCRs can resemble antibodies in recognizing conformational epitopes on MHC-independent ligands...
  70. ncbi request reprint Comparison of SUV and Patlak slope for monitoring of cancer therapy using serial PET scans
    Nanette M T Freedman
    Hadassah University Hospital, Jerusalem, Israel
    Eur J Nucl Med Mol Imaging 30:46-53. 2003
    ..However, when monitoring individual patient therapy serially, large differences in the % changes in the two indices were occasionally found, sometimes sufficient to produce opposing conclusions regarding the progression of disease...
  71. pmc Induction of CD4(+) T cell-dependent antitumor immunity by TAT-mediated tumor antigen delivery into dendritic cells
    Helen Y Wang
    Center for Cell and Gene Therapy and Department of Immunology, Baylor College of Medicine, Houston, Texas 77030, USA
    J Clin Invest 109:1463-70. 2002
    ..These results suggest that a TAT-mediated antigen delivery system may have important clinical applications for cancer therapy...
  72. ncbi request reprint Innovations and challenges in renal cancer: consensus statement from the first international conference
    Michael B Atkins
    Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Clin Cancer Res 10:6277S-81S. 2004